The first-of-its-kind buprenorphine implant was approved by the Food and Drug Administration last week and it is expected to curb craving and withdrawal symptoms for opioids for up to six months.
The implant, Probuphine, delivers low doses of buprenorphine over the six-month treatment period. It is the size of a matchstick and is a new delivery method for buprenorphine, which has been used for many years in the treatment of opioid addiction.
“Opioid abuse and addiction have taken a devastating toll on American families. We must do everything we can to make new, innovative treatment options available that can help patients regain control over their lives,” said FDA Commissioner Dr. Robert M. Califf in a news release.
Probuphine is receiving rave reviews from health professionals because patients will not have to take a daily pill, which can become habit forming and lead to overdose. It is among several options used in the treatment of opioid dependence.
Learn more about the new buprenorphine implant by visiting TheRecoveryMiracle.com.